Business / Finance

RSS

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with PharmAbcine, Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and several emerging countries, including Thailand, Brazil and Russia.

18 Nov 2014

EKF Diagnostics and Joslin Diabetes Center enter collaborative relationship

EKF, has entered a collaborative relationship with Joslin Diabetes Center in support of the ongoing clinical and commercial translation of TNFR1 & 2 biomarkers.

From EKF Diagnostics 17 Nov 2014

Anthera Pharmaceuticals reports net loss of $7.0 million for third quarter 2014

Anthera Pharmaceuticals, Inc., today announced financial results and operational update for the third quarter ended September 30, 2014.

16 Nov 2014

Escalon Medical reports net loss of $458,959 for first quarter of fiscal 2015

Escalon Medical Corp. today announced its operating results for its fiscal 2015 first quarter ended September 30, 2014.

16 Nov 2014

Biosafe gears up its activities in China with major expansion of Shanghai-based operations

Following the full registration of its product range by the Chinese FDA last April, Biosafe is gearing up its activities in the People's Republic of China with a major expansion of its Shanghai-based operations, including staffing and facilities consolidation.

14 Nov 2014

CASI Pharmaceuticals announces net loss of $21.5M in third quarter 2014

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a primary focus on China, today reported financial results for the three and nine months ended September 30, 2014.

14 Nov 2014

PDL BioPharma receives $30.3M to conclude revenue interest contract with AxoGen

PDL BioPharma, Inc. (PDL) today announced that the company has received $30.3 million, in addition to previously received revenue interest payments, to conclude PDL's revenue interest agreement with AxoGen, Inc.

14 Nov 2014

China Pharma’s revenues decrease $5.5M to 31% in third quarter 2014

China Pharma Holdings, Inc. (NYSE MKT: CPHI) ("China Pharma" or the "Company"), an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced its financial results for the three months ended September 30, 2014.

14 Nov 2014

Isis Pharmaceuticals, AstraZeneca partner to develop new delivery methods for antisense oligonucleotides

AstraZeneca and Isis Pharmaceuticals Inc. today announced a strategic alliance to discover and develop novel delivery methods for antisense oligonucleotides.

14 Nov 2014

Concordia Healthcare reports record revenues of 147% in third quarter 2014

Concordia Healthcare Corp. ("Concordia" or the "Company"), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced its financial and operational results for the three and nine months ended September 30, 2014.

14 Nov 2014

Amedica, Spinal Kinetics sign multi-year OEM agreement for silicon nitride spinal implants

Amedica Corporation, a biomaterial company that has developed silicon nitride ceramics as a material platform to manufacture and commercialize orthopedic implants, is pleased to announce that it has entered into a multi-year original equipment manufacturer (OEM) agreement with Spinal Kinetics, a leading innovator of advanced spinal implant technologies.

12 Nov 2014

PGI net sales increase 72.3% to $498.0 million in third quarter 2014

Polymer Group, Inc. reported results of operations for the third quarter ended September 27, 2014.

12 Nov 2014

Unilife submits 10-Q report for first quarter of FY 2015

Unilife Corporation ("Unilife" or "Company"), a developer and supplier of injectable drug delivery systems, today announced that it has submitted for filing its 10-Q report for the first quarter of Fiscal Year 2015 ending September 30, 2014.

11 Nov 2014

Linden Care announces new national contract under Comprehensive Hub Solutions Program

Linden Care LLC, a leading provider of comprehensive specialty pharmacy solutions to the pain management industry and a portfolio company of BelHealth Investment Partners, announced a new national contract under its Comprehensive Hub Solutions Program (the "Program").

11 Nov 2014

MicroMatrices, Advanced Cell Diagnostics sign preferred partnership agreement

MicroMatrices, a service provider specialised in high resolution cell type-specific analysis to characterise toxicological responses in different cell types in tissue, today announced a preferred partnership agreement with Advanced Cell Diagnostics, Inc., a leader in the field of molecular pathology and developer of cell and tissue-based analysis tools.

From Advanced Cell Diagnostics 11 Nov 2014

Ranir acquires Oralys Dental

Building on its position as a global leader in private label consumer oral and personal health care products, Ranir, today announced it has acquired Oralys Dental, the leading provider of private label toothbrushes in France.

10 Nov 2014

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2014.

10 Nov 2014

Johnson & Johnson completes acquisition of Alios BioPharma

Johnson & Johnson today announced the completion of the acquisition of Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for a total purchase price of approximately $1.75 billion in cash.

8 Nov 2014

Stradis Healthcare signs definitive agreement to acquire Medikmark

Stradis Healthcare is pleased to announce that it has entered into a definitive acquisition agreement with Medikmark, a leading provider of healthcare kits based in Waukegan, IL, under which Stradis will acquire all shares of Medikmark.

7 Nov 2014

Isis receives $10 million from Biogen Idec to initiate IND-supporting studies of ISIS-BIIB3 Rx

Isis Pharmaceuticals, Inc. announced today that it has earned a $10 million milestone payment from Biogen Idec related to the initiation of investigational new drug (IND)-supporting studies of ISIS-BIIB3Rx. ISIS-BIIB3Rx is a recently identified development candidate designed to inhibit an undisclosed target to treat a neurodegenerative disease.

6 Nov 2014